Travere Therapeutics (TVTX) Research & Development (2013 - 2026)

Travere Therapeutics' Research & Development history runs 14 years deep, the most recent figure standing at $57.1 million for Q1 2026.

• Quarterly Research & Development rose 21.76% year-over-year to $57.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $216.2 million (up 0.58% YoY) and the FY2025 annual result came in at $206.0 million, down 5.28% from the prior year.
• Research & Development was $57.1 million for Q1 2026 at Travere Therapeutics, down from $57.9 million in the prior quarter.
• Across five years, Research & Development topped out at $66.5 million in Q2 2023 and bottomed at $46.9 million in Q1 2025.
• A 5-year average of $56.3 million and a median of $57.1 million in 2022 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2024 — Research & Development declined 18.29% — and 2026, when it advanced 21.76%.
• Travere Therapeutics' Research & Development stood at $58.1 million in 2022, then increased by 2.86% to $59.7 million in 2023, then climbed by 3.88% to $62.1 million in 2024, then slipped by 6.76% to $57.9 million in 2025, then retreated by 1.34% to $57.1 million in 2026.
• Business Quant data shows TVTX's Research & Development at $57.1 million in Q1 2026, $57.9 million in Q4 2025, and $51.9 million in Q3 2025.